What an AI DNA Analysis Report Can and Cannot Tell You

An AI DNA analysis report is a language model summarizing an annotated variant file. The quality of the report is set almost entirely by what goes into it: the sequencing depth, the variant caller, the annotation databases, and whether the model was given structured evidence or asked to recall genetics from memory. If you hand a model a raw 23andMe text file and ask for a health report, you get fluent text built on roughly 600,000 genotyped positions out of 3.1 billion, most of them chosen for ancestry and common-trait association rather than clinical relevance. If you hand it an annotated VCF from a 30x whole genome, plus the annotation sources it should cite, you get something you can check line by line. This page is about how to build the second thing.

What the model is reading

A useful report starts from a variant call format (VCF) file, which lists positions where your genome differs from the reference, along with genotype, depth, and quality. A 30x germline whole-genome VCF typically contains four to five million variants for a single person. Almost all of them are common and uninformative. The interpretive work is filtering.

The model never reads your raw reads. It reads annotations attached to variants by tools that ran before it. So the annotation step is where accuracy is won or lost. We annotate with Ensembl VEP or bcftools csq to get consequence terms. Then we join in population frequency from gnomAD v4, clinical assertions from ClinVar, and pharmacogenomic star alleles from PharmVar or PharmGKB.

A minimal pipeline that produces a model-ready file:

bcftools view -f PASS -i 'FMT/DP>=10 & FMT/GQ>=20' input.vcf.gz -Oz -o filtered.vcf.gz

vep -i filtered.vcf.gz -o annotated.vcf --vcf --cache --offline \
  --assembly GRCh38 --everything --pick_allele_gene \
  --custom gnomad.genomes.v4.sites.vcf.gz,gnomAD,vcf,exact,0,AF,AF_popmax \
  --custom clinvar.vcf.gz,ClinVar,vcf,exact,0,CLNSIG,CLNREVSTAT

Then reduce to something a model can hold in context. Keep variants with ClinVar pathogenic or likely-pathogenic assertions at two-star review status or better. The loss-of-function consequences are stop_gained, frameshift_variant, splice_acceptor_variant, and splice_donor_variant. Keep them where gnomAD popmax allele frequency is below 0.001. That usually leaves tens to low hundreds of rows. Ship those rows as a table, with the evidence fields intact, and require the model to cite the field it used for each claim.

Why the source data matters more than the model

The dominant failure mode of AI DNA reports is confident interpretation of positions that were never measured well, or never measured at all. Bad reasoning is not the main problem.

Genotyping arrays interrogate fixed sites. They cannot see a novel frameshift in a gene they do not probe, and many array “pathogenic variant” calls are false positives because the probes were designed for common variation rather than rare alleles. Whole-exome sequencing covers the roughly 1.5% of the genome that codes for protein, which is where most known Mendelian disease variants sit. Exome sequencing became the standard discovery tool for single-gene disorders precisely because that fraction of the genome carries a disproportionate share of high-impact alleles.¹ Whole-genome sequencing adds intronic, regulatory, and structural variation. It also gives more even coverage than exome capture.

Depth drives confidence at a specific position. At 30x mean coverage, individual sites can still land at 8x or 10x, and a heterozygous call at 8x has a real chance of being missed or miscalled. When a report makes a claim about one variant, we check the depth and genotype quality for that variant rather than trusting the file-level average. A well-built prompt gives the model DP and GQ and instructs it to flag anything below your threshold as unconfirmed.

Two further limits are worth stating plainly. Short-read sequencing calls structural variants and repeat expansions poorly, so it will not reliably characterize expansions in genes like HTT or FMR1. And pharmacogenomic genes such as CYP2D6 involve copy-number changes and hybrid alleles that generic callers get wrong. They need dedicated tools like Cyrius or Aldy.

Where AI adds real value

The strength of a model is not recalling which variant does what. Curated databases do that better. The value shows up in three places.

The first is triage across many evidence sources at once. A model can hold your variant table, your gene-level coverage, and the relevant literature in one context and produce a ranked list of what deserves a second look. Reviews of machine learning in genomics describe this integrative role: models assist in prioritizing variants and generating hypotheses across data types rather than issuing verdicts.²

The second is multi-omic integration, which is where single-genome reports usually stop. A DNA variant is a static prior. Whether the associated gene is expressed in your tissue, and at what level, comes from RNA sequencing. Whether a protein is present at abnormal concentration comes from proteomics. Regulatory state comes from methylation, and integrative analyses across methylation and expression data have been used to surface shared regulators and pathways that neither layer showed alone.³ A model that reads your variant table alongside RNA counts and a protein panel can ask whether a predicted loss-of-function allele shows any downstream effect in you.

The third is following change over time. Cross-sectional genomes describe what you inherited. Sequential sampling describes what is happening. Whole-genome data from tumor cell populations has been used to reconstruct which mutations drove rapid growth and in what order, which is only visible when you can compare samples rather than read one.⁴ The same logic applies at much lower stakes to your own proteomic and expression baselines: the second measurement is what makes the first one interpretable.

How to prompt so the output is checkable

Treat the model as a report generator over supplied evidence. Do not treat it as a knowledge source. Three rules do most of the work.

Give it the evidence table and forbid outside claims. Every statement in the report must reference a row and a field, for example ClinVar CLNSIG or gnomAD AF. If the field is absent, the model says so.

Ask for calibration language tied to data. Do not accept vibes. For each finding, require the following.

• gene
• transcript
• HGVS notation
• genotype
• DP
• GQ
• gnomAD popmax frequency
• ClinVar review status

A finding with one-star review status and no population frequency is a lead. It is not a result.

Require an explicit not-assessed section. Ask the model to list genes with mean coverage below 20x, regions with known callability problems, and variant classes the pipeline cannot detect. Readers consistently overestimate coverage, and the absence of a finding is the most misread part of any genomic report.

Nothing in this workflow constitutes a diagnosis. Clinical interpretation of a pathogenic variant requires confirmatory testing in an accredited laboratory and a clinical geneticist or genetic counselor who can place it against your family history. Research-grade sequencing is not a substitute for that. Formal genetic evaluation follows staged, guideline-driven protocols for exactly this reason, because the order of tests and the confirmation step change what a result means.⁵

Questions people also ask

What is the Ancestry.com scandal?

Ancestry has drawn recurring criticism and litigation over consent and data handling rather than over sequencing accuracy. The recurring themes are how genetic data and family trees are used for research and marketing, how law enforcement requests are handled, and what happens to your sample and data if the company is acquired. Read the current terms before uploading, and prefer providers that give you the raw files so you are not dependent on their interface.

How long after DNA is analyzed do you get results?

Consumer array kits typically run six to eight weeks from mailing. Clinical whole-exome or whole-genome sequencing generally reports in two to six weeks, with rapid protocols in acute settings compressing that to days. Sequencing itself is fast: a whole-genome run takes roughly one to two days, and direct-from-sample whole-genome workflows have been demonstrated for drug resistance profiling on comparable timescales.⁶ Most of the elapsed time is logistics, bioinformatics, and human review.

How far back is 1% DNA ethnicity?

Roughly five to seven generations, meaning ancestors born somewhere in the early to mid nineteenth century. The arithmetic is loose because recombination is stochastic. You inherit about 50% from each parent but not exactly 25% from each grandparent, and a single ancestor’s contribution can drop to zero within about eight generations. Treat any single-digit percentage as a noisy estimate of similarity to a reference panel rather than a fact about a specific ancestor.

Can you look up DNA test results online?

You can download your own raw data from most consumer providers, and you should. Look for a Download Raw Data option that yields a tab-delimited genotype file. A sequencing provider may instead give you a VCF, BAM, or FASTQ. Your results are not searchable by others, though DNA relative-matching features expose you to matches by design. Genetic data in forensic and research contexts can be recovered and amplified from extremely small inputs, down to single-cell quantities, which is a useful reminder of how little material identification requires.⁷

Footnotes

1. Michael J. Bamshad, Sarah B. Ng, Abigail W. Bigham, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nature Reviews Genetics, 2011. https://doi.org/10.1038/nrg3031 ↩

2. Alexandra-Maria Blaga, Răzvan-Octavian Mihuț, Andreea-Ramona Treteanu, et al. Artificial Intelligence and Genomic Data Analysis: New Frontiers in Precision Medicine. International Journal of Molecular Sciences, 2026. https://doi.org/10.3390/ijms27156755 ↩

3. Shicai Fan, Jianxiong Tang, Nan Li, et al. Integrative analysis with expanded DNA methylation data reveals common key regulators and pathways in cancers. npj Genomic Medicine, 2019. https://doi.org/10.1038/s41525-019-0077-8 ↩

4. Yong Tao, Jue Ruan, Shiou-Hwei Yeh, et al. Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proceedings of the National Academy of Sciences, 2011. https://doi.org/10.1073/pnas.1108715108 ↩

5. Leigh Anne Flore, Jeff M. Milunsky. Updates in the Genetic Evaluation of the Child with Global Developmental Delay or Intellectual Disability. Seminars in Pediatric Neurology, 2012. https://doi.org/10.1016/j.spen.2012.09.004 ↩

6. Camus Nimmo, Ronan Doyle, Carrie Burgess, et al. Rapid identification of a Mycobacterium tuberculosis full genetic drug resistance profile through whole genome sequencing directly from sputum. International Journal of Infectious Diseases, 2017. https://doi.org/10.1016/j.ijid.2017.07.007 ↩

7. Erin K. Hanson, Jack Ballantyne. Whole genome amplification strategy for forensic genetic analysis using single or few cell equivalents of genomic DNA. Analytical Biochemistry, 2005. https://doi.org/10.1016/j.ab.2005.08.017 ↩